Abstract: The immature platelet fraction (IPF) is an automated parameter available on specific Sysmex analysers to quantitate reticulated platelets. The current clinical utility and limitations of this test are reviewed in this article. The IPF offers the ability to assess whether thrombocytopenia is caused by increased platelet consumption/destruction or failure of production. An elevated IPF% has been reported as an aid to the diagnosis of ITP, or as an early indicator of bone marrow recovery after stem cell transplantation or chemotherapy. Prophylactic platelet transfusions may be able to be reduced by using the rise in IPF% as an early predictor of platelet regeneration. The IPF has been proposed as an indicator of thrombotic risk in reactive thrombocytosis or that associated with myeloproliferative neoplasms, renal transplantation and cardiovascular disease. New areas of study of the usefulness of this parameter include disseminated intravascular coagulation, anti-platelet therapy, sepsis, liver cirrhosis, and myelodysplastic syndromes. It may have future applications in monitoring the effectiveness of treatment of thrombocytopenia. Its disadvantages include its limited availability, strict stability requirements, lack of standardisation and there is no external quality assurance program.
To cite this article: Sinclair, Leanne. The immature platelet fraction: Where is it now? [online]. Australian Journal of Medical Science, Vol. 33, No. 1, Mar 2012: 10-17.
[cited 25 Jun 16].
Source: Australian Journal of Medical Science, Vol. 33, No. 1, Mar 2012: 10-17
Document Type: Journal Article
Blood platelets--Examination; Blood platelets--Transfusion; Thrombocytopenia; Blood platelet disorders--Diagnosis; Genetic markers; Patient monitoring;
Identifier: Immature platelet fraction (IPF)
(1) Wesley Laboratory, Sullivan Nicolaides Pathology, Suite 54, Sandford Jackson Building, 30 Chasely Street, Auchenflower Qld 4066, Brisbane, Queensland, Email: email@example.com
Database: Health Collection